Novel |
ABL1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
- Regulation of actin dynamics for phagocytic cup formation
- Role of ABL in ROBO-SLIT signaling
- Role of ABL in ROBO-SLIT signaling
- Myogenesis
- Myogenesis
- RHO GTPases Activate WASPs and WAVEs
- HDR through Single Strand Annealing (SSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Cyclin D associated events in G1
- RUNX1 regulates transcription of genes involved in differentiation of HSCs
- RUNX2 regulates osteoblast differentiation
- FCGR3A-mediated phagocytosis
- Factors involved in megakaryocyte development and platelet production
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
|
- ATP
- Imatinib
- Dasatinib
- N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
- Nilotinib
- XL228
- Bosutinib
- 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
- 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
- Myristic acid
- PD-166326
- 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
- 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
- Regorafenib
- Ponatinib
- Fostamatinib
- Brigatinib
- Radotinib
- Asciminib
- Umbralisib
|
- Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
- Chronic myeloid leukemia (CML)
|
Novel |
ACTN1 |
actinin alpha 1 |
- Platelet degranulation
- Syndecan interactions
- Nephrin family interactions
- Regulation of cytoskeletal remodeling and cell spreading by IPP complex components
- RHOD GTPase cycle
- RHOBTB2 GTPase cycle
- RHOF GTPase cycle
|
|
|
Novel |
ADAM12 |
ADAM metallopeptidase domain 12 |
- Signaling by EGFR
- Invadopodia formation
|
|
|
Novel |
ADAM15 |
ADAM metallopeptidase domain 15 |
- Degradation of the extracellular matrix
- Invadopodia formation
|
|
|
Novel |
ADRB2 |
adrenoceptor beta 2 |
- Adrenoceptors
- G alpha (s) signalling events
- Ub-specific processing proteases
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
|
- Spermine
- Amphetamine
- Betaxolol
- Bethanidine
- Isoetharine
- Cabergoline
- Metoprolol
- Metoprolol
- Olanzapine
- Atenolol
- Norepinephrine
- Timolol
- Phenylpropanolamine
- Dipivefrin
- Sotalol
- Carteolol
- Nortriptyline
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Paroxetine
- Trimipramine
- Cryptenamine
- Orciprenaline
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Ritodrine
- Terbutaline
- Bitolterol
- Phenoxybenzamine
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Ergoloid mesylate
- Isoprenaline
- Arbutamine
- Amiodarone
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Aripiprazole
- Arformoterol
- Fenoterol
- Pirbuterol
- Bevantolol
- Penbutolol
- Ephedra sinica root
- Ephedrine
- Mephentermine
- Procaterol
- Clenbuterol
- Bambuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Nebivolol
- Indacaterol
- Bedoradrine
- NCX 950
- Asenapine
- Droxidopa
- Bufuralol
- Protokylol
- (S)-carazolol
- Bopindolol
- Bupranolol
- Befunolol
- Olodaterol
- Vilanterol
- Viloxazine
- Arotinolol
- Doxofylline
- Racepinephrine
- Dihydroergocornine
- DL-Methylephedrine
- Etafedrine
- Tulobuterol
- Levosalbutamol
- Dihydroergocristine
- Methoxyphenamine
|
|
Novel |
ADRB3 |
adrenoceptor beta 3 |
- Adrenoceptors
- G alpha (s) signalling events
|
- Amphetamine
- Bethanidine
- Metoprolol
- Dihydroergotamine
- Olanzapine
- Norepinephrine
- Nortriptyline
- Propranolol
- Paroxetine
- Trimipramine
- Cryptenamine
- Alprenolol
- Ritodrine
- Terbutaline
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Ergoloid mesylate
- Isoprenaline
- Arbutamine
- Amiodarone
- Fenoterol
- Ephedra sinica root
- Mephentermine
- Clenbuterol
- Oxprenolol
- Celiprolol
- Nebivolol
- Amibegron
- Solabegron
- Droxidopa
- Bufuralol
- Bopindolol
- Bupranolol
- Mirabegron
- Racepinephrine
- Dihydroergocornine
- DL-Methylephedrine
- Dihydroergocristine
- Vibegron
|
|
Novel |
AFAP1 |
actin filament associated protein 1 |
|
|
|
Novel |
AFAP1L2 |
actin filament associated protein 1 like 2 |
|
|
|
Novel |
AGAP1 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 |
|
|
|
Novel |
AHR |
aryl hydrocarbon receptor |
- PPARA activates gene expression
- Phase I - Functionalization of compounds
- Endogenous sterols
- Xenobiotics
- Aryl hydrocarbon receptor signalling
|
- Omeprazole
- Mexiletine
- Nimodipine
- Flutamide
- Atorvastatin
- Leflunomide
- Ginseng
- Indirubin-3'-monoxime
- Resveratrol
- Quercetin
- Tapinarof
- beta-Naphthoflavone
- Emodin
- 1-[(4S)-4-amino-5-(1,3-benzothiazol-2-yl)-5-oxopentyl]guanidine
- Diosmin
- Kynurenic Acid
- Epigallocatechin gallate
- Cantharidin
- Indirubin
- Carbendazim
- Indigo
|
|
Novel |
AKT1 |
AKT serine/threonine kinase 1 |
- Activation of BAD and translocation to mitochondria
- PIP3 activates AKT signaling
- PIP3 activates AKT signaling
- Downregulation of ERBB2:ERBB3 signaling
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- MTOR signalling
- AKT phosphorylates targets in the cytosol
- AKT phosphorylates targets in the cytosol
- AKT phosphorylates targets in the nucleus
- Negative regulation of the PI3K/AKT network
- eNOS activation
- AKT-mediated inactivation of FOXO1A
- Integrin signaling
- Deactivation of the beta-catenin transactivating complex
- CD28 dependent PI3K/Akt signaling
- Co-inhibition by CTLA4
- G beta:gamma signalling through PI3Kgamma
- Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
- KSRP (KHSRP) binds and destabilizes mRNA
- VEGFR2 mediated vascular permeability
- TP53 Regulates Metabolic Genes
- Constitutive Signaling by AKT1 E17K in Cancer
- Interleukin-4 and Interleukin-13 signaling
- Regulation of TP53 Degradation
- Regulation of TP53 Activity through Acetylation
- Regulation of TP53 Activity through Association with Co-factors
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Cyclin E associated events during G1/S transition
- Cyclin A:Cdk2-associated events at S phase entry
- PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
- RAB GEFs exchange GTP for GDP on RABs
- RUNX2 regulates genes involved in cell migration
- Regulation of PTEN stability and activity
- Extra-nuclear estrogen signaling
- Negative regulation of NOTCH4 signaling
- FLT3 Signaling
- Regulation of localization of FOXO transcription factors
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- KEAP1-NFE2L2 pathway
- SARS-CoV-2 targets host intracellular signalling and regulatory pathways
- Mitochondrial unfolded protein response (UPRmt)
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
- Mechanical load activates signaling by PIEZO1 and integrins in osteocytes
|
- ATP
- Arsenic trioxide
- Genistein
- Inositol 1,3,4,5-Tetrakisphosphate
- Resveratrol
- Archexin
- Enzastaurin
- Perifosine
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
|
- PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
|
Novel |
ALDOB |
aldolase, fructose-bisphosphate B |
- Hereditary fructose intolerance
- Glycolysis
- Gluconeogenesis
- Fructose catabolism
|
- 1,6-Fructose Diphosphate (Linear Form)
- sn-glycerol 3-phosphate
- Dihydroxyacetone phosphate
|
- Hereditary fructose intolerance; Fructosemia
|
Novel |
ANKRD11 |
ankyrin repeat domain containing 11 |
|
|
|
Novel |
ANXA1 |
annexin A1 |
- G alpha (q) signalling events
- G alpha (i) signalling events
- Formyl peptide receptors bind formyl peptides and many other ligands
- Smooth Muscle Contraction
- Interleukin-4 and Interleukin-13 signaling
- Developmental Lineage of Pancreatic Ductal Cells
|
- Amcinonide
- Fluocinolone acetonide
- Hydrocortisone
- Methylprednisolone
- Clobetasol propionate
- Budesonide
- Dexamethasone
- Cortisone acetate
- Hydrocortisone aceponate
- Hydrocortisone acetate
- Hydrocortisone butyrate
- Hydrocortisone cypionate
- Hydrocortisone phosphate
- Hydrocortisone probutate
- Hydrocortisone valerate
- Prednisolone phosphate
- Dexamethasone acetate
- Betamethasone phosphate
|
|
Novel |
ANXA2 |
annexin A2 |
- Smooth Muscle Contraction
- Neutrophil degranulation
- Dissolution of Fibrin Clot
- Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
- Developmental Lineage of Pancreatic Ductal Cells
|
- Tenecteplase
- Fluocinolone acetonide
- Lanoteplase
- Artenimol
|
|
Novel |
ANXA7 |
annexin A7 |
|
|
|
Novel |
AR |
androgen receptor |
- HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
- Ub-specific processing proteases
- RUNX2 regulates osteoblast differentiation
- RUNX2 regulates osteoblast differentiation
|
- Diethylstilbestrol
- Levonorgestrel
- Progesterone
- Spironolactone
- Flutamide
- Oxandrolone
- Fluphenazine
- Testosterone
- Mitotane
- Estrone
- Nilutamide
- Tamoxifen
- Norethisterone
- Drostanolone
- Norgestimate
- Nandrolone phenpropionate
- Ketoconazole
- Acetophenazine
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone propionate
- Oxybenzone
- 1-Testosterone
- Boldenone
- Calusterone
- Periciazine
- Prasterone
- Flufenamic acid
- Stanolone
- (R)-Bicalutamide
- Metribolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone acetate
- LGD2941
- Dimethylcurcumin
- Oxymetholone
- Methyltestosterone
- Norelgestromin
- Stanozolol
- Tetrahydrogestrinone
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- BMS-564929
- S-23
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- Andarine
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- LGD-2226
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Triclosan
- Nandrolone decanoate
- Ulipristal
- Enzalutamide
- Eugenol
- Dienogest
- Norethynodrel
- Norgestrel
- Homosalate
- Enzacamene
- Luprostiol
- Mibolerone
- Phenothiazine
- Gestrinone
- Apalutamide
- Clascoterone
- Darolutamide
- Esculin
- Ligandrol
- Testosterone cypionate
- Testosterone enanthate
- Testosterone undecanoate
- Stanolone acetate
- Segesterone acetate
- Boldenone undecylenate
- Echinacoside
- Ketodarolutamide
|
- Spinal and bulbar muscular atrophy (SBMA); Kennedy's disease
- 46,XY disorders of sex development (Other), including: Persistent Mullerian duct syndrome; Hypospadias; Cryptorchidism
- Prostate cancer
- 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
|
Novel |
ARHGAP1 |
Rho GTPase activating protein 1 |
- RHOA GTPase cycle
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOD GTPase cycle
- RHOQ GTPase cycle
- RHOG GTPase cycle
- RHOJ GTPase cycle
- RAC3 GTPase cycle
- RHOF GTPase cycle
- RND2 GTPase cycle
|
|
|
Novel |
ARHGAP17 |
Rho GTPase activating protein 17 |
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOD GTPase cycle
- RHOQ GTPase cycle
- RAC3 GTPase cycle
|
|
|
Novel |
ARHGAP32 |
Rho GTPase activating protein 32 |
- RHOA GTPase cycle
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOD GTPase cycle
- RHOQ GTPase cycle
- RHOG GTPase cycle
- RHOJ GTPase cycle
- RAC3 GTPase cycle
- RHOF GTPase cycle
- Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
|
|
|